BR112017020769A2 - anticorpo ou fragmento de ligação, seq id no:3 ou seq id no:7, conjugado de anticorpo-fármaco (adc), composição farmacêutica, processo para produzir a composição farmacêutica, kit para diagnosticar um indivíduo que sofre de um distúrbio neurodegenerativo, método para diagnosticar um indivíduo que sofre de um distúrbio neurodegenerativo, uso do anticorpo ou fragmento de ligação, uso ex vivo de um peptídeo t14, método para identificar um agente candidato, ensaio para identificar um agente, método para identificar um agente que modula - Google Patents
anticorpo ou fragmento de ligação, seq id no:3 ou seq id no:7, conjugado de anticorpo-fármaco (adc), composição farmacêutica, processo para produzir a composição farmacêutica, kit para diagnosticar um indivíduo que sofre de um distúrbio neurodegenerativo, método para diagnosticar um indivíduo que sofre de um distúrbio neurodegenerativo, uso do anticorpo ou fragmento de ligação, uso ex vivo de um peptídeo t14, método para identificar um agente candidato, ensaio para identificar um agente, método para identificar um agente que modulaInfo
- Publication number
- BR112017020769A2 BR112017020769A2 BR112017020769A BR112017020769A BR112017020769A2 BR 112017020769 A2 BR112017020769 A2 BR 112017020769A2 BR 112017020769 A BR112017020769 A BR 112017020769A BR 112017020769 A BR112017020769 A BR 112017020769A BR 112017020769 A2 BR112017020769 A2 BR 112017020769A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- identifying
- agent
- sequence
- pharmaceutical composition
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 4
- 239000003795 chemical substances by application Substances 0.000 title 3
- 239000012634 fragment Substances 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 2
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 229940049595 antibody-drug conjugate Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 238000003745 diagnosis Methods 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Psychology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1505239.2A GB201505239D0 (en) | 2015-03-27 | 2015-03-27 | Antibody |
| GB1600871.6A GB2541477A (en) | 2015-03-27 | 2016-01-18 | Antibody |
| PCT/GB2016/050804 WO2016156803A1 (en) | 2015-03-27 | 2016-03-23 | Antibody that recognises the t14 peptide of ache |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017020769A2 true BR112017020769A2 (pt) | 2018-06-26 |
Family
ID=53178191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017020769A BR112017020769A2 (pt) | 2015-03-27 | 2016-03-23 | anticorpo ou fragmento de ligação, seq id no:3 ou seq id no:7, conjugado de anticorpo-fármaco (adc), composição farmacêutica, processo para produzir a composição farmacêutica, kit para diagnosticar um indivíduo que sofre de um distúrbio neurodegenerativo, método para diagnosticar um indivíduo que sofre de um distúrbio neurodegenerativo, uso do anticorpo ou fragmento de ligação, uso ex vivo de um peptídeo t14, método para identificar um agente candidato, ensaio para identificar um agente, método para identificar um agente que modula |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10954306B2 (enExample) |
| EP (1) | EP3274371B1 (enExample) |
| JP (1) | JP7327897B2 (enExample) |
| KR (1) | KR102626626B1 (enExample) |
| CN (1) | CN107531796A (enExample) |
| AU (1) | AU2016240020B2 (enExample) |
| BR (1) | BR112017020769A2 (enExample) |
| CA (1) | CA2979972A1 (enExample) |
| ES (1) | ES2952723T3 (enExample) |
| GB (2) | GB201505239D0 (enExample) |
| MX (1) | MX392158B (enExample) |
| RU (1) | RU2729491C2 (enExample) |
| WO (1) | WO2016156803A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2539161A (en) * | 2014-11-26 | 2016-12-14 | Neuro-Bio Ltd | Neurodegenerative disorders |
| GB2546773B (en) * | 2016-01-28 | 2020-06-17 | Neuro Bio Ltd | Cancer |
| GB201705044D0 (en) * | 2017-03-29 | 2017-05-10 | Neuro-Bio Ltd | Biomarker |
| US12227567B2 (en) | 2017-07-25 | 2025-02-18 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| CN116063520A (zh) | 2019-01-30 | 2023-05-05 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| GB202112831D0 (en) * | 2021-09-09 | 2021-10-27 | Neuro Bio Ltd | Biomarker |
| GB202113941D0 (en) | 2021-09-29 | 2021-11-10 | Neuro Bio Ltd | Skin biomarker |
| CA3267108A1 (en) | 2022-09-08 | 2024-03-14 | Neuro-Bio Ltd | LATERAL FLOW DEVICE FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE USING THE T14 PEPTIDE |
| GB202308779D0 (en) * | 2023-06-13 | 2023-07-26 | Neuro Bio Ltd | Aptamer |
| GB202308799D0 (en) | 2023-06-13 | 2023-07-26 | Neuro Bio Ltd | Neurodegenerative disease |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9606040D0 (en) * | 1996-03-22 | 1996-05-22 | Isis Innovation | Active peptide |
| EP1269201A1 (en) | 2000-03-29 | 2003-01-02 | Synaptica Limited | Alpha 7 nicotinic receptor screening assays |
| GB0028578D0 (en) * | 2000-11-23 | 2001-01-10 | Synaptica Ltd | Screening assays |
| GB0502068D0 (en) * | 2005-02-01 | 2005-03-09 | King S College London | Screening method |
| PT1915626E (pt) * | 2005-08-16 | 2012-02-03 | Genentech Inc | Sensibilidade da apoptose a apo2l/trail por ensaio de expressão de galnac-t14 em células/tecidos |
| GB0708646D0 (en) * | 2007-05-04 | 2007-06-13 | Enkephala Ltd | Biologically active C-terminal fragment of acetylcholinesterase |
| WO2009040789A2 (en) * | 2007-09-24 | 2009-04-02 | Technion Research & Development Foundation Ltd. | T cell subpopulations capable of treating cancer |
| CN101530162B (zh) * | 2008-03-10 | 2011-11-23 | 北京大北农科技集团股份有限公司 | 一种新型蛋白饲料添加剂的制备方法 |
-
2015
- 2015-03-27 GB GBGB1505239.2A patent/GB201505239D0/en not_active Ceased
-
2016
- 2016-01-18 GB GB1600871.6A patent/GB2541477A/en not_active Withdrawn
- 2016-03-23 ES ES16713029T patent/ES2952723T3/es active Active
- 2016-03-23 CN CN201680021081.0A patent/CN107531796A/zh active Pending
- 2016-03-23 RU RU2017133649A patent/RU2729491C2/ru active
- 2016-03-23 MX MX2017012397A patent/MX392158B/es unknown
- 2016-03-23 WO PCT/GB2016/050804 patent/WO2016156803A1/en not_active Ceased
- 2016-03-23 KR KR1020177027589A patent/KR102626626B1/ko active Active
- 2016-03-23 US US15/561,021 patent/US10954306B2/en active Active
- 2016-03-23 EP EP16713029.3A patent/EP3274371B1/en active Active
- 2016-03-23 BR BR112017020769A patent/BR112017020769A2/pt active Search and Examination
- 2016-03-23 JP JP2017550514A patent/JP7327897B2/ja active Active
- 2016-03-23 AU AU2016240020A patent/AU2016240020B2/en not_active Ceased
- 2016-03-23 CA CA2979972A patent/CA2979972A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB201600871D0 (en) | 2016-03-02 |
| GB2541477A (en) | 2017-02-22 |
| ES2952723T3 (es) | 2023-11-03 |
| JP7327897B2 (ja) | 2023-08-16 |
| JP2018516849A (ja) | 2018-06-28 |
| RU2729491C2 (ru) | 2020-08-07 |
| KR102626626B1 (ko) | 2024-01-17 |
| AU2016240020A1 (en) | 2017-11-02 |
| EP3274371B1 (en) | 2023-06-07 |
| MX392158B (es) | 2025-03-21 |
| AU2016240020B2 (en) | 2022-02-17 |
| CN107531796A (zh) | 2018-01-02 |
| EP3274371A1 (en) | 2018-01-31 |
| WO2016156803A1 (en) | 2016-10-06 |
| RU2017133649A (ru) | 2019-04-29 |
| US20180051094A1 (en) | 2018-02-22 |
| MX2017012397A (es) | 2018-01-26 |
| US10954306B2 (en) | 2021-03-23 |
| CA2979972A1 (en) | 2016-10-06 |
| KR20170138414A (ko) | 2017-12-15 |
| RU2017133649A3 (enExample) | 2020-02-17 |
| GB201505239D0 (en) | 2015-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017020769A2 (pt) | anticorpo ou fragmento de ligação, seq id no:3 ou seq id no:7, conjugado de anticorpo-fármaco (adc), composição farmacêutica, processo para produzir a composição farmacêutica, kit para diagnosticar um indivíduo que sofre de um distúrbio neurodegenerativo, método para diagnosticar um indivíduo que sofre de um distúrbio neurodegenerativo, uso do anticorpo ou fragmento de ligação, uso ex vivo de um peptídeo t14, método para identificar um agente candidato, ensaio para identificar um agente, método para identificar um agente que modula | |
| JOP20180117A1 (ar) | أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها | |
| JO3711B1 (ar) | أجسام مضادة محددة لبروتين تاو وطرق استعمالها | |
| MX356800B (es) | Anticuerpo tau humanizado. | |
| BR112018000696A2 (pt) | ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit? | |
| PH12021552334A1 (en) | Antibodies to pyroglutamate amyloid-ã and uses thereof | |
| BR112018070097A2 (pt) | anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos | |
| MY164376A (en) | Phosphospecific antibodies recognizing tau | |
| BR112014006376A2 (pt) | terapia baseada em proteínas e diagnóstico de patologia mediada por tau em doença de alzheimer | |
| MX354662B (es) | Anticuerpos fosfoespecificos que reconocen la tau. | |
| BR112019012040A2 (pt) | anticorpo isolado ou fragmento do mesmo, composição, célula isolada, e, métodos para tratamento de câncer, para detecção da expressão de cd73 em uma amostra e para identificação de um paciente com câncer adequado para o tratamento com uma terapia anti-cd73. | |
| PE20200152A1 (es) | Receptores de union a antigeno mejorados | |
| EA033433B1 (ru) | Антитела к tau и их применение | |
| EP3906945A3 (en) | Nucleic acids encoding human antibodies to sialyl-lewis a | |
| BR112014018592A2 (pt) | composição e método para o diagnóstico e tratamento de doenças associadas à degeneração de neuritos | |
| EA201692192A1 (ru) | СВЯЗЫВАЮЩЕЕСЯ С FcRn АНТИТЕЛО ДЛЯ ЛЕЧЕНИЯ АУТОИММУННЫХ ЗАБОЛЕВАНИЙ | |
| CO2021011944A2 (es) | Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer | |
| BR112014029089A2 (pt) | anticorpo ou um fragmento de ligação de antígeno do mesmo; polinucleótido codificador; composto; composição/formulação farmacêutica; kit; uso; método in vitro para reduzir ou inibir a atividade da enzima tg2 | |
| BR112013021056A2 (pt) | anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical | |
| CO2021008204A2 (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso | |
| WO2017027685A3 (en) | Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy | |
| MY179845A (en) | Specific biomarker set for non-invasive diagnosis of liver cancer | |
| EA202090116A1 (ru) | Композиции, содержащие конъюгаты каннабиноидного аналога, и способы применения | |
| BR112017022205A2 (pt) | anticorpo anti-vegfr2 humano para terapia de câncer antiangiogênica e objetivada | |
| BR112021017863A2 (pt) | Proteína de ligação de antígeno de membrana específico de próstata, composição, método para produzir a proteína de ligação de antígeno de membrana específico de próstata |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE 3A. ANUIDADE. |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |